Manila Bulletin: "332 COVID-19 patients in PH now participating in WHO Solidarity Trials"

 

By Jeffrey Damicog
Article link:  https://news.mb.com.ph/2020/06/26/332-covid-19-patients-in-ph-now-participating-in-who-solidarity-trials/

 

 

 

There are now 332 patients afflicted with the 2019 novel coronavirus disease (COVID-19) in the country who are participating in the World Health Organization’s (WHO) global Solidarity Trial, Department of Science and Technology (DOST) Secretary Fortunato dela Pena said on Friday, June 26.

 

Department of Science and Technology Secretary Fortunato dela Peña (TOTO LOZANO/ Presidential Photo / MANILA BULLETIN)

Department of Science and Technology Secretary Fortunato dela Peña (TOTO LOZANO/ Presidential Photo / MANILA BULLETIN)

 

“Tumaas na ulit ang bilang ng ating mga subjects na enrolled para sa WHO Solidarity Trials (The number of subjects who enrolled for the WHO Solidarity Trials have increased again),” De la Pena said during his weekly online briefing.

“Ngayon ay nasa 332 patients na ang enrolled dito (There are now 332 patients enrolled),” he reported.

De la Pena said the 332 patients are currently confined in 21 hospitals which are part of the 24 hospitals approved to participate in the Solidarity Trials. The WHO aims to have 5,000 patients participating globally.

Among the 21 participating hospitals, seven are public hospitals and 14 private hospitals.

De la Pena said the DOST is funding the Solidarity Trials in the country with P29.99 million.

“Ito ay ini-implement ng ating National Institute of Health, University of the Philippines at ang aim nito is to assess and provide reliable estimates on any effects of several repurposed antivirals. (This is being implemented by the UP’s National Institute of Health and its aim is to assess and provide reliable estimates on any effects of several repurposed antivirals),” the secretary explained.

Under the trials, he explained patients have been divided into five groups: those not being given the medicines in the WHO list; those given remdesivir; those given chloroquine; those given lopinavir with ritonavir; and those given lopinavir with ritonavir plus interferon.

Meanwhile, De la Pena said the DOST’s Philippine Council for Health Research (DOST-PCHRD) and the Research Institute for Tropical Medicine (RITM) has begun their COVID-19 Transmission Study project.

The secretary explained this is “a prospective study of close contacts of COVID-19 confirmed cases at the RITM.”

He added that the study is being funded by the DOST for P4.985 million.

“The study will determine the transmission of the disease to help improve and guide efforts to understand the transmission of COVID-19 and prevent further spread of the disease,” he said.

“The transmission patterns and the disease severity will help in the characterization, spectrum of the disease and impact in the community,” he added.

The secretary said the information that will be gathered from this study will be used as “a guide in formulating guidelines for case isolations, for contact tracing, and disease control and prevention.”